The Global Fertility Alliance supports the identification and establishment of standards for fertility treatment and the harmonization of Assisted Reproductive Technology (ART) processes, as well as the focusing on ART education in collaboration with medical societies.
The Alliance represents an opportunity to bring alignment and higher consistency to ART practices worldwide and aims to deliver a positive impact for healthcare professionals, fertility labs, and most importantly, their patients.
The Alliance began as a partnership between Illumina, Merck KGaA, Darmstadt, Germany, and Genea Biomedx in June 2015, launched at European Society of Human Resproduction and Embryology (ESHRE) in Lisbon, Portugal. Initiatives in the first year included hosting an educational symposium at the annual Alpha meeting in May 2016 and collaborating with KOLs on a white paper to examine variables in the IVF workflow and describe how each variable can be optimized to achieve the best possible outcomes for patients. At ESHRE 2016, the GFA announced the addition of two new members, Hamilton Thorne and ZEISS.
Goals of the GFA
- To create a collaborative alliance of technology vendors dedicated to raising awareness of the need for standardization and automation in In Vitro Fertilization (IVF) clinics with the aim to optimize ART processes to a consistently high level across the industry and nations.
- To provide guidance to the IVF clinics and practitioners on the application of automated and standardized technologies in the ART labs.
- To offer integrated education spanning ART technologies globally to increase knowledge and improve access to ART technologies for families affected by infertility.
- To collaborate with medical societies to support evolving guidelines for ART.